Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the USA just published online.
Hernandez-Villafuerte, K., Li, R., Towse, A. and Chalkidou, K.
This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa, Uganda, China, India, Indonesia, Myanmar, Philippines, Thailand and Vietnam).
This OHE Occasional Paper by Adrian Towse discusses Professor Bengt Jönsson’s observations in a 2011 publication about the role of relative effectiveness research (RE) in the European medicines market and how this could lead to improved efficiency in the development of medicines, the pricing and use of medicines, and of health systems.
Rejon-Parrilla, J.C., Hernandez-Villafuerte, K., Shah, K., Mestre-Ferrandiz, J., Garrison, L. and Towse, A.
This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.
This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to assess biosimilars – including which methods are most appropriate in specific situations. Participating were ten experts: leading academics and representatives from the UK medicines regulatory agency, the three UK HTA entities, and the UK industry trade association. Background for discussion at the meeting included an OHE literature review and ABPI’s 2013 position paper on biosimilar medicines.